Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 2/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1229637 | 0.79 | LOXL2 (0.60) | IDO1OPRK1LOXL2HDAC3HDAC1 | |
| SCHEMBL11982489 | 0.78 | OPRK1 (0.57) | IDO1OPRK1LOXL2HDAC3HDAC1 | |
| SCHEMBL325463 | 0.78 | LOXL2 (0.58) | IDO1LOXL2MTNR1AMTNR1BCYP2A6 | |
| SCHEMBL31105584 | 0.78 | LOXL2 (0.58) | IDO1LOXL2MTNR1AMTNR1BCYP2A6 | |
| SCHEMBL8184923 | 0.77 | LOXL2 (0.53) | IDO1OPRK1LOXL2HDAC3HDAC1 | |
| SCHEMBL4104078 | 0.77 | OPRK1 (0.73) | IDO1OPRK1LOXL2HDAC3HDAC1 | |
| SCHEMBL28876221 | 0.76 | LOXL2 (0.56) | IDO1LOXL2MTNR1AMTNR1BCYP2A6 | |
| SCHEMBL28876206 | 0.76 | LOXL2 (0.56) | IDO1LOXL2MTNR1AMTNR1BCYP2A6 | |
| Bromide SCHEMBL27641073 | 0.76 | LOXL2 (0.56) | IDO1LOXL2MTNR1AMTNR1BCYP2A6 | |
| Ammonia Solution, Strong SCHEMBL28873731 | 0.76 | LOXL2 (0.56) | IDO1LOXL2MTNR1AMTNR1BCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024031155-A1 | RADIOPHARMACEUTICALS | AdvanCell Isotopes Pty Limited (AU) | 2024-02-15 | — | — | WO | disclosed |
| EP-2721045-B1 | COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS | RADIOMEDIX INC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9550001-B2 | Compositions, methods of synthesis and use of carbohydrate targeted agents | RADIOMEDIX INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140228551-A1 | COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS | RADIOMEDIX INC. (US) | 2014-08-14 | — | — | US | disclosed |
| EP-2721045-A2 | COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS | Radiomedix Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012177701-A2 | COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS | RADIOMEDIX INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| EP-1794122-B1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMA INC (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7923466-B2 | treating in a lengthening of circadian rhythm period with 6-aminomethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide; for treating central nervous system diseases and mood disorders, bipolar disorder and sleep disorders, with an enzyme inhibitor | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7629376-B2 | 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase I | AVENTIS PHARMACEUTICALS INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090082340-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080027124-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2008-01-31 | — | — | US | disclosed |
| EP-1794122-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | Aventis Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006023467-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Iϵ | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082340-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | CSNK2A3, CSNK1G3, CSNK1G1 | IDO1 60/4885OPRK1 53/4885LOXL2 3151/4885 |
| US-20140228551-A1 | COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS | SLC2A2, SLC2A3, SLC2A1 | IDO1 4042/4885OPRK1 1495/4885LOXL2 4242/4885 |
| US-20080027124-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | CSNK1G3, CSNK2A3, CSNK1E | IDO1 76/4885OPRK1 53/4885LOXL2 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.